Search for a trial

OMIT trial: omitting therapeutic lymph node dissection in patients with stage IIIB/C melanoma and major pathological response in the index lymph node after neoadjudvant immunotherapy

To investigate whether TLND can be safely omitted in patients with macroscopic resectable stage III (B/C/D) melanoma achieving an MPR within the ILN upon neoadjuvant treatment with nivolumab in combination with ipilimumab.